Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 1Leukemia, Plasma Cell 1

Interventions

Melphalan 5fludarabine phosphate 3fludarabine 3Whole-Body Irradiation 3Peripheral Blood Stem Cell Transplantation 3Mycophenolic Acid 3Cyclophosphamide 3Tacrolimus 2pomalidomide 1ixazomib 1elotuzumab 1dexamethasone acetate 1dexamethasone 21-phosphate 1carmustine, poliferprosan 20 drug combination 1carfilzomib 1auricularum 1Stem Cell Transplantation 1Sirolimus 1Panobinostat 1Lenalidomide 1High-Throughput Screening Assays 1Gemcitabine 1Filgrastim 1Etoposide 1Dexamethasone 1Cytarabine 1Carmustine 1Calcium Dobesilate 1Busulfan 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia, Plasma Cell × High-Throughput Screening Assays × Clear all
NCT03389347 2026-05-08

High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

University of Washington

Phase NA Active not recruiting
40 enrolled 7 charts
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡